Morgan Stanley Analysts Give GW Pharmaceuticals PLC- (GWPH) a $227.00 Price Target

GW Pharmaceuticals PLC- (NASDAQ:GWPH) has been given a $227.00 price target by analysts at Morgan Stanley in a report issued on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price points to a potential upside of 58.39% from the stock’s current price.

Other equities analysts also recently issued research reports about the stock. ValuEngine downgraded shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a report on Thursday, August 2nd. Cantor Fitzgerald set a $235.00 price target on shares of GW Pharmaceuticals PLC- and gave the company a “buy” rating in a report on Thursday, July 12th. Stifel Nicolaus assumed coverage on shares of GW Pharmaceuticals PLC- in a report on Tuesday, August 14th. They set a “buy” rating and a $181.00 price target on the stock. BidaskClub raised shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Saturday, August 11th. Finally, Zacks Investment Research downgraded shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a report on Friday, August 10th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $185.00.

Shares of NASDAQ:GWPH opened at $143.32 on Thursday. The company has a current ratio of 8.67, a quick ratio of 8.21 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals PLC- has a 1-year low of $101.07 and a 1-year high of $179.65. The company has a market cap of $4.80 billion, a price-to-earnings ratio of -20.62 and a beta of 2.61.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating the consensus estimate of ($2.40) by $1.14. GW Pharmaceuticals PLC- had a negative net margin of 1,392.61% and a negative return on equity of 47.65%. The business had revenue of $3.46 million for the quarter, compared to the consensus estimate of $2.00 million. On average, equities research analysts predict that GW Pharmaceuticals PLC- will post -9.11 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. Dorsey Wright & Associates bought a new stake in shares of GW Pharmaceuticals PLC- during the third quarter valued at approximately $7,106,000. Gofen & Glossberg LLC IL bought a new stake in shares of GW Pharmaceuticals PLC- during the third quarter valued at approximately $356,000. Atria Investments LLC bought a new stake in shares of GW Pharmaceuticals PLC- during the third quarter valued at approximately $331,000. Bank of New York Mellon Corp raised its position in shares of GW Pharmaceuticals PLC- by 134.9% during the second quarter. Bank of New York Mellon Corp now owns 13,053 shares of the biopharmaceutical company’s stock valued at $1,822,000 after buying an additional 7,496 shares during the last quarter. Finally, Verition Fund Management LLC bought a new stake in shares of GW Pharmaceuticals PLC- during the second quarter valued at approximately $322,000. Hedge funds and other institutional investors own 75.44% of the company’s stock.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Further Reading: Understanding Price to Earnings Ratio (PE)

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply